A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
This is a single cohort observational safety study. All patients will be treated and
 monitored according to the local clinical practice. No additional procedures/patient visits
 in comparison with the usual clinical practice are planned for the study. Data will be
 collected from centre's medical records for up to 5 years or death.
Inclusion Criteria:

 -  All patients who are considered candidates to receive Herceptin for this indication

 Exclusion Criteria:

 -  Patients for whom Herceptin is contraindicated